-
ESMO China’s Voice丨Dr. Fei Ma: Breakthrough Advances in Breast Cancer Treatment with New Trop-2 ADC Drug ESG401
The 2024 European Society for Medical Oncology (ESMO 2024) Annual Meeting will be held from September 13-17 in Barcelona, Spain. At this upcoming ESMO 2024 conference, Dr. Fei Ma from the Cancer Hospital Chinese Academy of Medical Sciences and Peking Union Medical College will present two Mini Oral reports (344MO, 349MO) on the novel Trop-2…
-
ESMO 2024丨Highlighting Key Clinical Questions: Dr. Lin Shen’s Three Studies Featured in ESMO Poster Presentations
From September 13 to 17, 2024, the highly anticipated European Society for Medical Oncology (ESMO) Annual Meeting took place in Barcelona, Spain. At this prestigious event, three cutting-edge research projects led by Dr. Lin Shen from Peking Cancer Hospital were successfully selected for poster presentations, showcasing the remarkable contributions of Chinese scholars in the field…
-
Dr. Jin Zhang: Deep Dive into Precision Treatment for Breast Cancer, Understanding the Current Status of Anti-HER2 Therapy and Clinical Practice
From August 2 to 4, 2024, the 7th Oncology Precision Diagnosis and Treatment and the 10th Breast Cancer Individualized Treatment Conference (COMB), hosted by the China Cancer Foundation and the Beijing Breast Disease Prevention and Treatment Society, took place in Beijing. This conference focused on the development of individualized precision treatment in the field of…
-
ESMO International Perspective | Dr. Hitomi Sakai: The OLZ-based Triple Therapy Offers a New Strategy for Nausea and Vomiting in Breast Cancer Patient
At the 2024 European Society for Medical Oncology (ESMO) Annual Congress, Dr. Hitomi Sakai from the Advanced Cancer Translational Research Institute in Japan reported on the significant efficacy of the OLZ-based triple therapy in preventing treatment-related nausea and vomiting (NV) in patients treated with T-DXd, providing an important reference for clinical practice. After the conference,…
-
Dr. Peter Schmid：KEYNOTE-522 Study OS Results Update, Pembrolizumab Reshapes the Treatment Landscape for Early TNBC patients
At the 2024 ESMO Congress, Dr. Peter Schmid from Barts Cancer Institute, Queen Mary University of London shared the overall survival data from the KEYNOTE-522 study with a follow-up of 75.1 months. The long-term follow-up results of the study showed that the combination of immunotherapy and chemotherapy significantly extended the event-free survival and overall survival…
-
Sino-Foreign Dialogue on the Banks of the Yangtze River: Experts’ High-end Talks to Explore the Frontiers and Cooperation Paths of Viral Hepatitis Res
Hepatology Digest：Both of you have made remarkable achievements in the research field of hepatitis virus infections. May I ask what are the breakthrough discoveries regarding new therapeutic targets for hepatitis…
-
Dr Wai-Kay Seto’s Team: Optimized Glycemic Control Reduces Hepatocellular Carcinoma and Liver-Related Mortality in Patients with Diabetes
Introduction Hepatocellular carcinoma (HCC) is the most common form of primary liver cancer and the third leading cause of cancer-related deaths globally. What makes HCC particularly dangerous is its high…
-
China’s Prestigious Oncology Event: 2024 CSCO Annual Meeting Held in Xiamen
Xiamen, China, September 25-29, 2024 — The 27th National Clinical Oncology Conference and the 2024 Academic Annual Meeting of the Chinese Society of Clinical Oncology (CSCO) commenced in Xiamen, embracing the theme “Patient-Centric, Shared Future.” Jointly organized by the CSCO and the CSCO Foundation, the conference has brought together top experts and elites in oncology…
Connecting Medical Expertise through Media